We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Learn about FibroScan, an ultrasound-based test that measures liver stiffness and scarring, and its role in detecting potential signs of liver cancer. Understand the procedure, results, and when to consult a doctor.

A FibroScan is a non-invasive medical imaging test that utilizes ultrasound technology to assess the health of your liver. It's also known as transient elastography (TE). Unlike a traditional ultrasound that provides visual images, a FibroScan specifically measures the stiffness of your liver tissue. This stiffness is a key indicator of liver damage, such as fibrosis (scarring) and cirrhosis. By analyzing how sound waves travel through the liver, the device can quantify the degree of stiffness, providing valuable information about the overall health of the organ.
The test is performed much like a standard ultrasound. A trained healthcare professional will apply a probe to the skin over your right upper abdomen, where the liver is located. The probe emits sound waves that penetrate the liver, and the device measures how quickly these waves return. The speed at which the waves travel is directly related to the stiffness of the liver tissue. Denser, stiffer tissue will transmit sound waves faster than healthy, pliable tissue.
The results of a FibroScan are typically reported in kilopascals (kPa), which is a unit of pressure. These readings help doctors understand the extent of liver scarring:
In addition to these fibrosis stages, specific kPa values can indicate:
A high liver stiffness reading, particularly over 20 kPa, can raise suspicion for liver cancer, as significant scarring is often associated with the disease.
While FibroScan is not primarily designed to directly diagnose liver cancer, it can play a crucial role in its detection. The test's ability to measure liver stiffness and identify fibrosis is particularly relevant because fibrosis is closely linked to hepatocellular carcinoma (HCC), the most common form of liver cancer. Studies have shown that individuals with certain liver conditions, like hepatitis C with cirrhosis, who have a high FibroScan reading (e.g., over 24 kPa), are more likely to be diagnosed with HCC.
Researchers have concluded that FibroScan can be a useful tool in identifying individuals who may be at higher risk for liver cancer. It helps narrow down the patient population that might benefit from further diagnostic procedures, such as a biopsy, to confirm the presence of cancer. Therefore, while it doesn't provide a definitive cancer diagnosis on its own, it serves as a valuable screening and risk assessment tool.
Preparing for a FibroScan is relatively straightforward. You will typically be asked to fast for at least 3 hours before the test. During this fasting period, you can only consume clear liquids like water. It's advisable to wear comfortable, loose-fitting clothing, as the probe will be placed on your upper right abdomen. Before the test begins, you might be asked to lie down and rest for a few minutes to ensure the most accurate readings.
The procedure itself is quick and painless. The healthcare provider will apply a water-based gel to your skin and then place the probe over the targeted area. You may be asked to hold your breath briefly during the scan. The entire process usually takes about 10 to 15 minutes.
Since FibroScan is a non-invasive procedure, there is no recovery period. You can resume your normal activities immediately after the test is completed and leave the clinic or hospital. Your results will typically be available within a few days, and your doctor will discuss them with you in detail.
It is essential to consult a doctor if you have any risk factors for liver disease or liver cancer, such as a history of hepatitis B or C, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), or diabetes. If you experience symptoms like unexplained weight loss, jaundice (yellowing of the skin and eyes), abdominal pain or swelling, or fatigue, seek medical attention promptly. A doctor may recommend a FibroScan as part of your diagnostic workup if they suspect liver issues.
Preventing liver cancer often involves managing underlying liver conditions and adopting a healthy lifestyle. Key preventive measures include:
No, a FibroScan is a painless, non-invasive test. You may feel a slight pressure from the probe, but there is no discomfort associated with the ultrasound waves.
FibroScan is not a direct diagnostic tool for liver cancer. However, it is highly effective at detecting liver stiffness and fibrosis, which are strong indicators of conditions that can lead to liver cancer. It helps identify individuals who require further investigation for HCC.
There are virtually no risks associated with a FibroScan as it is a non-invasive imaging technique that uses sound waves, similar to a standard ultrasound.
The frequency of FibroScans depends on your specific liver condition and your doctor's recommendations. For individuals with advanced liver disease or those at high risk for HCC, regular monitoring with FibroScan may be advised.
FibroScan is primarily used to assess liver stiffness and fibrosis. While it can detect many conditions that cause scarring, it may not be suitable for diagnosing all types of liver disease. Your doctor will determine the most appropriate diagnostic tools for your situation.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026